Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells
- PMID: 12138332
- DOI: 10.1159/000064921
Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells
Abstract
Background: Adherence is considered a major virulence trait of Candida albicans. FK463 is a new investigational intravenous antifungal of the 'candin family' with potent in vitro and in vivo activity against Candida spp.
Objective: The aim of the present study was to investigate the effect of Micafungin (FK463) on Candida adherence to epithelial cells of azole-sensitive and azole-resistant C. albicans isolates.
Methods: An in vitro assay using microtest plate technology and fluorescence measurement was developed to compare the adherence of C. albicans SC5314 and of paired C. albicans isolates to epithelial cells in the presence and in the absence of FK463.
Results: FK463 showed a marked inhibitory effect on the adherence of C. albicans SC5314. The addition of FK463 reduced the adherence of C. albicans SC5314 to 90% of the value of control without drug. A dose-dependent adherence inhibition was observed with FK463 in the range of 10-0.015 microg ml(-1). The comparison of paired C. albicans isolates, either a fluconazole-susceptible and a fluconazole-resistant isolate of one patient, revealed no significant difference in the adherence behavior between azole-susceptible and azole-resistant.
Conclusion: Micafungin (FK463) has the capacity to reduce adherence of C. albicans azole-susceptible and azole-resistant strains to epithelial cells.
Copyright 2002 S. Karger AG, Basel
Similar articles
-
Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.Antimicrob Agents Chemother. 2000 Jun;44(6):1728-30. doi: 10.1128/AAC.44.6.1728-1730.2000. Antimicrob Agents Chemother. 2000. PMID: 10817741 Free PMC article.
-
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.Antimicrob Agents Chemother. 2000 Jan;44(1):57-62. doi: 10.1128/AAC.44.1.57-62.2000. Antimicrob Agents Chemother. 2000. PMID: 10602723 Free PMC article.
-
In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.J Antibiot (Tokyo). 2000 Oct;53(10):1175-81. doi: 10.7164/antibiotics.53.1175. J Antibiot (Tokyo). 2000. PMID: 11132964
-
[The future of antifungal agents. Non azole antifungal agents].Nihon Ishinkin Gakkai Zasshi. 1999;40(3):157-61. doi: 10.3314/jjmm.40.157. Nihon Ishinkin Gakkai Zasshi. 1999. PMID: 10423510 Review. Japanese.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
Cited by
-
Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.Drugs. 2008;68(15):2225-55. doi: 10.2165/00003495-200868150-00010. Drugs. 2008. PMID: 18840009 Review.
-
Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.Antimicrob Agents Chemother. 2009 Aug;53(8):3347-52. doi: 10.1128/AAC.01480-08. Epub 2009 Apr 13. Antimicrob Agents Chemother. 2009. PMID: 19364856 Free PMC article.
-
Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.Paediatr Drugs. 2009;11(4):271-91. doi: 10.2165/00148581-200911040-00006. Paediatr Drugs. 2009. PMID: 19566111 Review.
-
Candida infections of the genitourinary tract.Clin Microbiol Rev. 2010 Apr;23(2):253-73. doi: 10.1128/CMR.00076-09. Clin Microbiol Rev. 2010. PMID: 20375352 Free PMC article. Review.
-
Review of the pharmacology and clinical studies of micafungin.Drug Des Devel Ther. 2009 Dec 29;3:295-302. doi: 10.2147/dddt.s3242. Drug Des Devel Ther. 2009. PMID: 20054447 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous